Saturday, July 11, 2026

pharma · Melanoma · HIV Infections

Bristol Myers Squibb

Bristol-Myers Squibb is a pharma organization headquartered in STEINHAUSEN, CH. Primary therapeutic focus areas include Melanoma, HIV Infections, Prostate Cancer, Neoplasms by Site, Stomach Cancer. NovaPharmaNews links 4

3401 Princeton Pike, Lawrence Township, NJ 08648, US HQ
38,146 Employees
NMPA registrant Type
Company details
Clinical program

CC-122

Phase 1 · small molecule · Non-Hodgkin Lymphoma

CC-122 for Non-Hodgkin Lymphoma is a Phase 1 program (small_molecule) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

← All Bristol-Myers Squibb projects Phase 1 small molecule active

Internal code CA092-1000

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Bristol-Myers Squibb
Phase
Phase 1
Modality
small_molecule
Indication
Non-Hodgkin Lymphoma
Status
active
Trials
1

Clinical trials